CareRx (CRRX) AI Stock Analysis

• Market Cap: C$183.36M
• Dividend Yield: N/A
• Average Volume (3M): 48.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: -0.16%
• EPS Growth: 75.25%
• Country: CA
• Employees: 1,423
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 63,062,954
• 10 Day Avg. Volume: 116,367
• 30 Day Avg. Volume: 48,313
• PEG Ratio: 1.33
• Price to Book (P/B): 1.47
• Price to Sales (P/S): 0.34
• P/FCF Ratio: 4.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$4.06
• Price Target Upside: 34.88% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 53 Neutral
• Price Target: C$3.00 ▼(-0.33% Downside)

CareRx's overall stock score is primarily influenced by its financial performance challenges, including declining revenues and negative profitability metrics. Technical analysis provides mixed signals, with some longer-term support but short-term weakness. Valuation is a concern due to the negative P/E ratio and lack of dividend yield. However, positive corporate events, such as increased bed count and improved financial results, provide some optimism for future growth.

Positive Factors

Bed Growth

Infrastructure improvements provide good visibility for acceleration in bed growth.

Operational Improvements

Revenue per bed increased 3.5% year over year, showing operational improvements.

Negative Factors

EBITDA Performance

EBITDA fell short mainly on one time expenses.

Revenue Performance

The company posted a small miss on revenues and EBITDA due to lower than forecast revenue per bed.

CareRx Business Overview & Revenue Model

Company Description

CareRx (CRRX) is a leading provider of pharmacy services to seniors living in communities across Canada. The company operates within the healthcare sector, focusing primarily on providing comprehensive medication management and clinical pharmacy services to long-term care, retirement homes, and other institutional settings. CareRx is dedicated to improving health outcomes and enhancing the quality of life for its clients through innovative solutions and personalized care.

How the Company Makes Money

CareRx makes money primarily through contracts with long-term care facilities, retirement homes, and other institutional healthcare providers. These contracts typically involve the provision of medication dispensing, clinical pharmacy services, and medication management for residents. The company's revenue streams include fees for service delivery, medication supply, and consultation services. Additionally, CareRx may engage in partnerships with healthcare organizations and suppliers to optimize its service offerings and expand its market presence. The company's earnings are significantly influenced by the number of facilities it services, the scale of its operations, and its ability to maintain long-term client relationships.

CareRx Financial Statement Overview

Summary

CareRx demonstrates strong cash flow management and a healthy gross profit margin. However, challenges include stagnant revenue growth, negative net income, and significant debt levels, necessitating strategic focus on operational efficiency and growth opportunities.

Income Statement

CareRx's income statement shows moderate financial performance. The company has been struggling with profitability, as seen in the negative net income for TTM and annual periods. However, the gross profit margin is healthy at 29.5% TTM, demonstrating strong cost management relative to revenue. Revenue growth has been stagnant recently, indicating limited top-line expansion. The EBIT and EBITDA margins are modest, reflecting potential operational efficiencies but also suggesting room for improvement in cost control and revenue growth.

Balance Sheet

The balance sheet indicates a relatively high leverage, with a debt-to-equity ratio of 0.95 TTM, suggesting significant reliance on debt financing. Stockholders' equity has shown growth, albeit slowly, from 2021 to TTM. The equity ratio is moderate at 38.6% TTM, implying a balanced approach between debt and equity. However, the company's return on equity remains negative due to persistent net losses, indicating underperformance in generating returns on shareholders' investments.

Cash Flow

Cash flow analysis reveals a strong operating cash flow to net income ratio, indicating robust cash generation relative to net income losses. The free cash flow is positive and has shown growth, providing a buffer for investment and debt service. Despite investment in capital expenditures, the company maintains a positive free cash flow, which is a positive indicator of financial health. The company seems to manage its cash flows effectively, balancing operating needs with investment and financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	365.96M	366.71M	370.75M	381.73M	262.63M	162.20M
Gross Profit	108.09M	108.06M	84.72M	109.93M	75.28M	47.05M
EBITDA	25.14M	23.90M	24.65M	-610.00K	9.01M	4.15M
Net Income	-1.82M	-4.50M	-5.41M	-34.35M	-22.73M	-18.18M
Balance Sheet
Total Assets	218.31M	223.54M	231.89M	264.54M	282.82M	156.11M
Cash, Cash Equivalents and Short-Term Investments	8.69M	9.08M	7.03M	28.37M	35.63M	19.62M
Total Debt	81.87M	82.63M	97.86M	135.22M	125.57M	82.19M
Total Liabilities	131.36M	139.31M	150.37M	200.08M	200.53M	144.81M
Stockholders Equity	86.95M	84.23M	81.53M	64.46M	82.29M	11.30M
Cash Flow
Free Cash Flow	23.95M	29.88M	18.68M	8.72M	153.00K	-1.73M
Operating Cash Flow	31.78M	37.99M	27.38M	22.33M	7.27M	229.00K
Investing Cash Flow	-9.15M	-7.92M	-12.31M	-16.60M	-93.18M	-4.17M
Financing Cash Flow	-21.16M	-28.02M	-36.40M	-12.99M	101.91M	23.50M

CareRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CRRX, the sentiment is Positive. The current price of 3.01 is above the 20-day moving average (MA) of 2.88, above the 50-day MA of 2.91, and above the 200-day MA of 2.52, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 63.69 is Neutral, neither overbought nor oversold. The STOCH value of 76.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CRRX.

CareRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXE	73 Outperform	C$1.13B	13.68	65.09%	3.78%	8.68%	39.93%
WELL	70 Outperform	C$1.19B	30.45	-14.61%	―	17.19%	-191.01%
SIA	67 Neutral	C$1.71B	46.29	6.94%	5.09%	10.13%	1.30%
DR	66 Neutral	$272.87M	2.07	41.13%	2.47%	-35.35%	948.72%
CRRX	53 Neutral	C$183.36M	―	-2.17%	―	-0.16%	75.25%
Sector *	47 Neutral	C$213.29M	-1.44	-30.58%	3.10%	19.48%	-0.04%
PHA	41 Neutral	C$2.22M	―	-239.50%	―	3.03%	-410.90%

CareRx Corporate Events

CareRx Sees Growth with Increased Bed Count and Improved Financial Results

CareRx Corporation reported its financial results for the second quarter of 2025, highlighting a growth in bed count to 91,062, which is expected to drive future growth. The company’s revenue for the quarter was $91.4 million, showing a slight increase from the previous quarter. Adjusted EBITDA also improved to $8.0 million due to increased bed servicing and cost-saving initiatives. Net income rose to $0.6 million, a significant improvement from a net loss in the same quarter of the previous year. The Ontario Ministry of Health’s decision to pause changes to long-term care pharmacy funding, which would have reduced professional fees, is expected to positively impact CareRx’s financial stability.

The most recent analyst rating on (TSE:CRRX) stock is a Hold with a C$2.25 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.

CareRx to Discuss Q2 2025 Financial Results in Upcoming Conference Call

CareRx Corporation announced it will host a conference call to discuss its second quarter 2025 financial results on July 31, 2025. This event will provide stakeholders with insights into the company’s financial performance and operational strategies, potentially impacting its market position and investor relations.

The most recent analyst rating on (TSE:CRRX) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.

CareRx Announces Successful Election of Board Members at Annual Meeting

CareRx Corporation, a prominent provider of pharmacy services to seniors in Canada, announced the successful election of its board of directors during the Annual General Meeting of Shareholders. All proposed resolutions were passed, reinforcing the company’s leadership and strategic direction. This outcome supports CareRx’s continued focus on enhancing medication safety and efficiency in senior care facilities, potentially strengthening its market position and stakeholder confidence.

The most recent analyst rating on (TSE:CRRX) stock is a Buy with a C$3.75 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.